Literature DB >> 23351579

High-density lipoprotein levels are strongly associated with the recovery rate of insulin sensitivity during the acute phase of myocardial infarction: a study by euglycemic hyperinsulinemic clamp.

Luiz Sergio F Carvalho1, Naiara V Martins, Filipe A Moura, Riobaldo M R Cintra, Osorio L R Almeida, Jose C Quinaglia e Silva, Andrei C Sposito.   

Abstract

BACKGROUND: The decrease of insulin sensitivity (IS) during myocardial infarction (MI) is strongly associated with increased morbidity and mortality. Recent data suggest that in individuals under stable conditions, high-density lipoprotein (HDL) may improve IS. To date, the role of HDL in the modulation of IS in acute metabolic stress conditions such as MI remains unknown.
OBJECTIVE: To explore the association between plasma HDL-C and the change in IS during the acute phase of MI.
METHODS: Consecutive nondiabetic patients with ST-segment elevation MI (n = 22) underwent direct measurement of IS through the euglycemic hyperinsulinemic clamp on the first morning and on the fifth day after onset of MI. Patients were grouped according to HDL-C levels at admission above and below the median value (35 mg/dL).
RESULTS: At admission, there was no significant difference in baseline IS index, clinical, anthropometric, or treatment characteristics between low and high HDL groups. Between admission and fifth day, there was a decrease of 8% in IS index in the low HDL group and an 11% increase in the high HDL group (P = .001 for intragroup and P = .012 for intergroup difference). This difference remained significant after we controlled for the sex, age, waist circumference, triglycerides, baseline IS index, and statin dose during hospitalization.
CONCLUSION: This is the first study to provide evidence that plasma levels of HDL-C are strongly associated with the recovery rate of IS during the acute phase of MI.
Copyright © 2013 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23351579     DOI: 10.1016/j.jacl.2012.10.003

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  2 in total

Review 1.  HDL and glucose metabolism: current evidence and therapeutic potential.

Authors:  Andrew L Siebel; Sarah Elizabeth Heywood; Bronwyn A Kingwell
Journal:  Front Pharmacol       Date:  2015-10-31       Impact factor: 5.810

2.  A Narrative Review and Expert Panel Recommendations on Dyslipidaemia Management After Acute Coronary Syndrome in Countries Outside Western Europe and North America.

Authors:  Ashraf Reda; Wael Almahmeed; Idit Dobrecky-Mery; Po-Hsun Huang; Ursulo Juarez-Herrera; Naresh Ranjith; Tobias Sayre; Miguel Urina-Triana
Journal:  Adv Ther       Date:  2020-03-29       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.